Aminocaproic acid manufacturers

Filters

Filters

Filters , active

Country of origin : South-korea
None products found

aminocaproic acid + neostigmine methylsulfate + naphazoline hydrochloride

Eye drops 1%+0.002%+0.002%

Dossier type
CTD
Dossier status
Ready to file
Country of origin
South Korea
GMP approvals
EU GMP
Manufacturer #11554
It is the leading pharmaceutical company specializing in ophthalmic products. The company has acquired EU GMP certification and has been under preparation for CGMP approval for both manufacturing sites of multi-dose and single-dose products.

Manufacturer usually replies in 4 business days

aminocaproic acid + neostigmine methylsulfate + naphazoline hydrochloride + chlorphenamine maleate

Eye drops 10 mg + 0.02 mg + 0.02 mg + 0.1 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
South Korea
GMP approvals
PICS
Manufacturer #13108
The company has a corporate mission of protecting precious human life from various forms of diseases. It is focused on improving the health status of the people. The company was established in the 1970s. They have grown in the ethical drug market specializing in IMDs and ophthalmic products.

aminocaproic acid + chlorphenamine maleate + naphazoline hydrochloride + neostigmine methylsulfate

Eye drops 10 mg + 0.1 mg + 0.02 mg + 0.02 mg - 14 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
South Korea
GMP approvals
PICS
Manufacturer #446
It was established in the late 1950s with one ideology of respect for life and customer first. One of the major achievements of the company is in the field of ophthalmic disease. All products are GMP certified. The manufacturer sells more than 150 prescription medicine which includes the circulatory and digestive system, as well as antibiotics. It is an international company that delivers pharmaceutical products to domestic and international markets in China, ASEAN countries, the Middle East, Africa, and more.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

About aminocaproic acid

Aminocaproic acid manufacturers include Epic Pharma (Amicar), Hikma, and US generic makers such as Vitruvias, Leading Pharma, Ajenat, Somerset and Sunny, plus producers in China, Japan and Russia. Aminocaproic acid is an antifibrinolytic that helps stop bleeding by preventing blood clots from breaking down. Pharmaceutical companies can source aminocaproic acid tablets, oral solution and injection through out-licensing, supply or technology transfer. Dossiers are available in US ANDA and CTD formats.

Aminocaproic acid key facts

Property

Aminocaproic acid

INN

Aminocaproic acid (epsilon-aminocaproic acid)

Chemical name

6-aminohexanoic acid

Molecular formula / weight

C6H13NO2 / 131.2 g/mol

CAS number

60-32-2

ATC code

B02AA01

Drug class

Antifibrinolytic

Brand name

Amicar (US)

US NDA

NDA 015197 (Amicar)

Dosage forms and strengths

Tablets 500 mg and 1,000 mg; oral solution 250 mg/ml; injection 250 mg/ml

Indications

To enhance haemostasis when fibrinolysis contributes to bleeding

Typical dose

4–5 g in the first hour, then 1–1.25 g per hour; maximum 30 g per day

US generics

Several, including oral solution approvals in 2018, 2021 and 2022

Patent status

Off-patent

Aminocaproic acid manufacturers and licensing history

Aminocaproic acid has been used since the 1960s and is sold in the US as Amicar. Epic Pharma holds the Amicar tablet and oral solution products, and Hikma supplies injection.

US generics are made by several companies, including Vitruvias and Leading Pharma for tablets. Generic oral solutions were approved for Sunny (2018), Ajenat (2021) and Somerset (2022). Aminocaproic acid is also widely used in China, Japan and Russia.

Aminocaproic acid API is simple to make and widely available. Buyers should confirm GMP status, a US DMF and the impurity profile before choosing a dossier partner.

Aminocaproic acid dosage forms and dossier types

Aminocaproic acid is approved as tablets, oral solution and injection. Generic aminocaproic acid manufacturers most often develop tablets and oral solution.

Form

Strengths

Typical dossier

Notes

Aminocaproic acid tablets

500 mg, 1,000 mg

US ANDA; CTD

Reference Amicar

Aminocaproic acid oral solution

250 mg/ml

US ANDA

Also used as mouthwash for dental bleeding

Aminocaproic acid injection

250 mg/ml

US ANDA; CTD

Hospital use; contains benzyl alcohol

Aminocaproic acid API

Bulk

US DMF

Widely available

Target market

Dossier format

Key requirement

United States

ANDA (eCTD)

Reference Amicar; bioequivalence

European Union

EU CTD

Check national reference products; tranexamic acid is more common

China, Russia, Asia

National CTD

Widely registered

Aminocaproic acid regulatory and patent status

Aminocaproic acid is long off-patent. Amicar remains the US reference product, and several generic tablets and oral solutions are approved. In much of Europe, tranexamic acid is used more often, so check whether a reference product is authorised in each target country.

Aminocaproic acid mechanism of action and therapeutic use

Aminocaproic acid blocks plasminogen activators and, to a lesser extent, plasmin itself. This stops fibrin clots from breaking down too quickly. It is used when excessive fibrinolysis contributes to bleeding, such as after heart surgery or in some bleeding disorders. It should not be used when there is active intravascular clotting.

Aminocaproic acid licensing and sourcing

Aminocaproic acid suppliers and licensing partners typically offer dossier out-licensing, finished-product supply or technology transfer. Buyers usually compare GMP status (EU GMP, US FDA or WHO GMP), dossier format and readiness, API source and territory availability. Current offers and supplier contacts are listed among the aminocaproic acid manufacturers on Pipelinepharma.

Frequently asked questions about aminocaproic acid

Who are the main aminocaproic acid manufacturers? Epic Pharma holds Amicar, and Hikma supplies injection in the US. Generic makers include Vitruvias, Leading Pharma, Ajenat, Somerset and Sunny.

Is there a generic version of aminocaproic acid? Yes. Generic aminocaproic acid tablets and oral solution are approved in the US, with oral solution approvals in 2018, 2021 and 2022.

What is the difference between aminocaproic acid and tranexamic acid? Both are antifibrinolytics. Tranexamic acid is about ten times more potent and is more widely used in Europe.

What forms and strengths of aminocaproic acid are available? Aminocaproic acid is available as 500 mg and 1,000 mg tablets, 250 mg/ml oral solution and 250 mg/ml injection.

Is an aminocaproic acid dossier available for licensing? Yes. Aminocaproic acid tablet, oral solution and injection dossiers are available in US ANDA and CTD formats.

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.